Journal of Endocrinological Investigation

, Volume 22, Issue 8, pp 646–652

The role of SERMs in the management of postmenopausal osteoporosis

Article

Key-words

SERMs postmenopausal osteoporosis hormone replacement therapy estrogen receptor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lindsay R., Hart D.M., Forrest C., Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980, ii: 1151–1153.CrossRefGoogle Scholar
  2. 2.
    Christiansen C., Christensen M.S., McNair P.L., Hagen C., Stocklund K.E., Transbøl I. Prevention of early menopausal bone loss: Conducted 2-year. Eur. J. Clin. Invest. 1980, 10: 273–279.PubMedCrossRefGoogle Scholar
  3. 3.
    Hutchinson A., Polansky S.M., Feinstein A.R. Postmenopausal estrogens protect against fractures of the hip and distal radius: a case control study. Lancet 1979, ii: 705–709.CrossRefGoogle Scholar
  4. 4.
    Weiss N.S., Ure C.L., Ballard J.H., Williams A.R., Daling J.R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N. Engl. J. Med. 1980, 303: 1195–1198.PubMedCrossRefGoogle Scholar
  5. 5.
    Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W.F., Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N. Engl. J. Med. 1987, 317: 1169–1174.PubMedCrossRefGoogle Scholar
  6. 6.
    Quigley M.E.T., Martin P.L., Burnier A.M., Brooks P. Estrogen therapy arrests bone loss in elderly women. Am. J. Obstet. Gynecol. 1987, 156: 1516–1523.PubMedCrossRefGoogle Scholar
  7. 7.
    Schneider D.L., Barrett-Connor E.L., Morton D.J. Timing of postmenopausal estrogen for optimal bone mineral density. JAMA 1997, 277: 543–547.PubMedCrossRefGoogle Scholar
  8. 8.
    Michaelsson K., Baron J.A., Farahmand B.Y., Johnell O., Magnusson C., Persson P.-G., Persson I., Ljunghall S. Hormone replacement therapy and risk of hip fracture: a case-control study. BMJ 1998, 316: 1858–1863.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332: 1589–1593.PubMedCrossRefGoogle Scholar
  10. 10.
    Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350: 1047–1059.CrossRefGoogle Scholar
  11. 11.
    Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348: 977–980.PubMedCrossRefGoogle Scholar
  12. 12.
    Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996, 348: 981–983.PubMedCrossRefGoogle Scholar
  13. 13.
    Grodstein F., Stampfer J.J., Goldhaber S.Z. Prospective study of exogenous hormones and risk of pulmonary embolism. Lancet 1996, 348: 983–987.PubMedCrossRefGoogle Scholar
  14. 14.
    Gutthann S.P., Garcia-Rodriguez L.A., Castellsague J., Oliart A.D. Hormone replacement therapy and risk of thromboembolism: population based case-control study. BMJ 1997, 314: 796–800.CrossRefGoogle Scholar
  15. 15.
    Beresford S.A.A., Weiss N.S., Voight L.F., McKnight B. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997, 349: 458–461.PubMedCrossRefGoogle Scholar
  16. 16.
    Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., Speizer F.E., Hennekens C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 1996, 335: 453–461.PubMedCrossRefGoogle Scholar
  17. 17.
    Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280: 605–613.PubMedCrossRefGoogle Scholar
  18. 18.
    Henderson V.W. The epidemiology of estrogen replacement therapy and Alzheimer’s disease. Neurology 1997, 48 (Suppl. 7): S27–S35.PubMedCrossRefGoogle Scholar
  19. 19.
    Newcomb P.A., Storer B. Postmenopausal hormone use and risk of large bowel cancer. J. Natl. Cancer. Inst. 1995, 87: 1067–1071.PubMedCrossRefGoogle Scholar
  20. 20.
    Compston J.E. The therapeutic use of bisphosphonates. BMJ 1994, 309: 711–715.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Storm T., Kollerup G., Thamsborg G., Genant H.K., Sørensen O.H. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J. Rheumatol. 1996, 23: 1560–1564.PubMedGoogle Scholar
  22. 22.
    Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., De Queker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C., Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 1995, 333: 1437–1443.PubMedCrossRefGoogle Scholar
  23. 23.
    Herd R.J.M., Balena R., Blake G.M., Ryan P.J., Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am. J. Med. 1997, 103: 92–99.PubMedCrossRefGoogle Scholar
  24. 24.
    Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M., Yates J. Prevention of bone loss with alendronate in postmenopausal women under sixty years of age. N. Engl. J. Med. 1998, 338: 485–492.PubMedCrossRefGoogle Scholar
  25. 25.
    Meunier P.J., Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1997, 21: 373–378.PubMedCrossRefGoogle Scholar
  26. 26.
    Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Gnsrud K.E. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348: 1535–1541.PubMedCrossRefGoogle Scholar
  27. 27.
    Ensrud K.E., Black D.M., Palermo L., Bauer D.C., Barrett Connor E., Quandt S.A., Thompson D.E., Karpf D.B. Treatment with alendronate prevents fractures in women at highest risk - Results from the fracture intervention trial. Arch. Intern. Med. 1997, 157: 2617–2624.PubMedCrossRefGoogle Scholar
  28. 28.
    Storm T., Thamsborg G., Steiniche T., Genant H.K., Sørensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 1990, 322: 1265–1271.PubMedCrossRefGoogle Scholar
  29. 29.
    Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C., Yanover M.J., Mysiw J., Kohse L., Rao M.B., Steiger P., Richmand B., Chesnut C.H. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1990, 323: 72–79.Google Scholar
  30. 30.
    Van Staa T.P., Abenhaim L., Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br. J. Rheumatol. 1998, 37: 87–94.PubMedCrossRefGoogle Scholar
  31. 31.
    de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., Wang K.K. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 1996, 335: 1016–1021.PubMedCrossRefGoogle Scholar
  32. 32.
    Meunier P.J., Confavreux E., Tupinon I., Hardouin C., Delmas P.D., Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy a double-blind, placebocontrolled study and 1-year follow-up. J. Clin. Endocrinol. Metab. 1997, 82: 2784–2791.PubMedGoogle Scholar
  33. 33.
    Overgaard K., Hansen M.A., Jensen S.B., Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992, 305: 556–561.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Kanis J.A., McCloskey E.V. Effect of calcitonin on vertebral and other fractures. Q. J. Med. 1999, 92: 143–149.CrossRefGoogle Scholar
  35. 35.
    Kanis J.A., Johnell O., Gullberg B., Allander E., Dilsen G., Gennari C., Vaz A.A.L., Lyritis G.P., Mazzuoli G., Miravet L., Passeri M., Cano R.P., Rapado A., Ribot C. Evidence for the efficacy of bone active drugs in the prevention of hip fracture. BMJ 1992, 305: 1124–1128.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Stock J.L., Avioli L.V., Baylink D.J., Chesnut C., Genant H.K., Maricic M.J., Silverman S.L., Schaffer A.V., Feinblatt J. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three-year interim results of the PROOF study. J. Bone Miner. Res. 1997, 12 (Suppl. 1): S149.Google Scholar
  37. 37.
    Compston J.E. Vitamin D deficiency in the elderly: time for action? BMJ 1998, 317: 1466–1467.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Chapuy M.C., Arlot M.E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P.D., Meunier P.J. Vitamin D3 and calcium to prevent hip fracture in elderly women. N. Engl. J. Med. 1992, 327: 1637–1642.PubMedCrossRefGoogle Scholar
  39. 39.
    Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N. Engl. J. Med. 1997, 337: 670–676.PubMedCrossRefGoogle Scholar
  40. 40.
    Heikinheimo R.J., Inkovaara J.A., Harju E.J. Annual injection of vitamin D and fracture of aged bones. Calcif. Tissue Int. 1992, 51: 105–110.PubMedCrossRefGoogle Scholar
  41. 41.
    Lips P., Graafmans W.C., Ooms M.E., Bezemer P.D., Bouter L.M. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 1996, 124: 400–406.PubMedCrossRefGoogle Scholar
  42. 42.
    Tilyard M.W., Spears G.F.S., Thomson J., Dovey A. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N. Engl. J. Med. 1992, 326: 357–362.PubMedCrossRefGoogle Scholar
  43. 43.
    Orimo H., Shiraki M., Hayashi Y., Hoshino T., Onaya T., Miyazaki S. Effects of 1alpha-hydroxyvitamin D3 on lumbar bone density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 1994, 54: 370–376.PubMedCrossRefGoogle Scholar
  44. 44.
    Ott S., Chesnut C.H. Calcitriol is not effective in postmenopausal osteoporosis. Ann. Intern. Med. 1989, 110: 267–274.PubMedCrossRefGoogle Scholar
  45. 45.
    Cumming R.G. Calcium intake and bone mass: a quantitative review of the evidence. Calcif. Tissue Int. 1990, 47: 194–201.PubMedCrossRefGoogle Scholar
  46. 46.
    Compston J.E. The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Clin. Endocrinol. 1995, 43: 393–405.CrossRefGoogle Scholar
  47. 47.
    Cumming R.G., Nevitt M.C. Calcium for prevention of osteoporotic fractures in postmenopausal women. J. Bone Miner. Res. 1997, 12: 1321–1329.PubMedCrossRefGoogle Scholar
  48. 48.
    Kleerekoper M. Fluoride: the verdict is in, but the controversy lingers. J. Bone Miner. Res. 1996, 11: 565–567.PubMedCrossRefGoogle Scholar
  49. 49.
    Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.-C., Shah A.S., Huster W.J., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337: 1641–1647.PubMedCrossRefGoogle Scholar
  50. 50.
    Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K., Riggs B.L. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J. Bone Miner. Res. 1998, 13: 1747–1754.PubMedCrossRefGoogle Scholar
  51. 51.
    Ensrud K., Black D., Recker R., Harris S., Delmas P., Pols H., Reginster J., Bjarnason N., Gennari C., Genant H., Knickerbocker R., Eastell R., Adachi J., Mitlak B. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Bone 1998, 23: S174.Google Scholar
  52. 52.
    Jordan V.C., Glusman J.E., Eckert S., Lippman M., Powles T., Costa A., Morrow M., Norton L., Lurie R.H. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, doubleblind, randomised trials in 12,000 postmenopausal women. Proc. Am. Soc. Clin. Oncol. 1998, 17: 122a.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1999

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Cambridge School of Clinical Medicine, Addenbrooke’s HospitalCambridgeUK
  2. 2.Dept. of MedicineAddenbrooke’s HospitalCambridgeUK

Personalised recommendations